758 related articles for article (PubMed ID: 31763951)
1. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
Henson B; Hollingsworth H; Nevois E; Herndon C
J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
Arca K; Reynolds J; Sands KA; Shiue HJ
Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
[No Abstract] [Full Text] [Related]
3. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
Breen ID; Brumfiel CM; Patel MH; Butterfield RJ; VanderPluym JH; Griffing L; Pittelkow MR; Mangold AR
JAMA Netw Open; 2021 Apr; 4(4):e217934. PubMed ID: 33871613
[TBL] [Abstract][Full Text] [Related]
6. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
7. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
8. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
9. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
10. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
11. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
Khan S; Olesen A; Ashina M
Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
[TBL] [Abstract][Full Text] [Related]
12. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
[TBL] [Abstract][Full Text] [Related]
13. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
Yuan H; White CS; Silberstein SD
Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
[TBL] [Abstract][Full Text] [Related]
16. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
17. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
18. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
20. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
